Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Allergan, Inc. (AGN): Is It Worth Looking At?

Novartis got sued

Novartis AG (NYSE:NVS) is also has a lower EV multiple than Allergan, Inc. (NYSE:AGN). The company is trading at $73.50 per share, with the total market cap of $180.6 billion. The company is valued at 11.4 times EV/EBITDA. According to the New York Times, at the end of April, Novartis was sued by the U.S. government, accusing the company of paying millions in kickback money to doctors in exchange for its drugs, including hypertension drugs Lotrel and Valturna, and the diabetes drug Starlis, being prescribed. In return, Novartis AG (NYSE:NVS)’ spokeswoman Julie Masow commented that Novartis would dispute the claims and defend itself.

Even after the legal issues, Novartis AG (NYSE:NVS)’ share price has consistently kept going up to nearly $73.50 per share. In February, it paid out more than $2.40 per share in dividends. Thus, the dividend yield stays at nearly 3.3%. Johnson & Johnson offers investors a bit lower dividend yield at 3.1% while the dividend yield for Allergan, Inc. (NYSE:AGN) is very small, at only 0.2%.

My Foolish take

Investing in the pharmaceutical industry is not easy. The results of the potential future pipelines of each company are uncertain. If potential growth is factored in, Allergan, Inc. (NYSE:AGN) seems to be the best pick with the lowest PEG at only 1.57% while the PEG ratios for Johnson & Johnson (NYSE:JNJ) and Novartis AG (NYSE:NVS) are much higher, at 2.42% and 2.73%, respectively. However, investors might feel much safer with Johnson & Johnson and Novartis because of their huge sizes, market leading positions and decent dividend yields.

The article Should We Get Bullish on This Fast Growing Healthcare Company? originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.